Lilly revenue rises 7.2 pct on higher demand for new drugs

Eli Lilly and Co reported a 7.2 percent rise in quarterly revenue, lifted by higher demand for its diabetes drug Trulicity and other new treatments.

The drugmaker said net income rose to $771.8 million, or 73 cents per share, in the fourth quarter ended Dec. 31, from $478.4 million, or 45 cents per share, a year earlier.

Revenue rose to $5.76 billion from $5.38 billion.